Annexon Inc. Company Profile
NASDAQ: ANNXHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Annexon at a glance
Annexon Inc. (NASDAQ: ANNX) is a Biotechnology company in the Healthcare sector headquartered in Brisbane, CA. Annexon is led by Mr. Douglas E. Love Esq., J.D. and employs about 92 people. The company's shares have traded publicly since 2020.
At a market capitalization of $760.2 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001528115, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Annexon do?
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Business description based on the company's public filings.
Company information
- Legal name
- Annexon Inc.
- Ticker
- NASDAQ: ANNX
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Douglas E. Love Esq., J.D.
- Employees
- 92
- Headquarters
- 1400 Sierra Point Parkway, Brisbane, CA, United States
- Phone
- 650 822 5500
- Website
- annexonbio.com
- IPO year
- 2020
- Market cap
- $760.21M
- SEC CIK
- 0001528115
Companies similar to Annexon
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DNAGinkgo Bioworks Holdings Inc. Class A | 11.34 | -1.13% | $763.64M | vs ANNX |
| ATTOAttovia Therapeutics Inc. | 16.31 | -0.67% | $744.57M | vs ANNX |
| CADLCandel Therapeutics Inc. | 9.66 | -1.63% | $739.17M | vs ANNX |
| VSTMVerastem Inc. | 8.11 | -1.88% | $734.47M | vs ANNX |
| OABIOmniAb Inc. | 4.66 | +2.19% | $677.52M | vs ANNX |
| ARDXArdelyx Inc. | 3.27 | +0.31% | $844.27M | vs ANNX |
| NVCTNuvectis Pharma Inc. | 20.13 | -0.79% | $657.12M | vs ANNX |
| SLNSilence Therapeutics Plc American Depository Share | 9.52 | -3.06% | $591.71M | vs ANNX |